Nautilus Biotechnology, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Nautilus Biotechnology, Inc. (NAUT) had Debt Securities, Available-for-sale, Unrealized Loss Position of $108.58 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-07-28
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $108.58M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $91.08M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $32.03M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $71.55M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $108.58M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $91.08M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $32.03M 10-K · filed 2026-02-26 |
| 2025-09-30 | $71.55M 10-Q · filed 2025-10-28 |
| 2024-12-31 | $92.57M 10-K · filed 2025-02-27 |
| 2024-09-30 | $100.40M 10-Q · filed 2024-10-29 |
| 2024-06-30 | $213.22M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $224.86M 10-Q · filed 2024-04-30 |
| 2023-12-31 | $186.94M 10-K · filed 2025-02-27 |
| 2023-09-30 | $274.15M 10-Q · filed 2023-10-31 |
| 2023-06-30 | $285.26M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $157.83M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $273.97M 10-K · filed 2024-02-28 |
| 2022-09-30 | $322.80M 10-Q · filed 2022-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |